Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial

Melero I., Reis B., Rusterholz C., Epp A., Kratochwil NA., Wu C., Hettich M., Kazantzidis G., Rieder N., Schwalie PC., Badillo S., Kumpesa N., Thommen A., Vugts DJ., Moreno V., Lostes Bardaji J., Alvarez EC., de Andrea CE., Spanggaard I., Lee DH., Spicer J., Thistlethwaite F., Oh D-Y., Hollebecque A., Cirovic O., Symeonides SN.

DOI

10.1038/s43018-026-01157-8

Type

Journal article

Publisher

Springer Science and Business Media LLC

Publication Date

2026-05-01T00:00:00+00:00

Volume

7

Pages

840 - 856

Total pages

16

Permalink More information Close